Stibbe advises Mylan

Stibbe advises Mylan

Stibbe advises Mylan


Stibbe advises Mylan Inc., the pharmaceuticals company listed on the NASDAQ with a market cap of approximately $19 billion, on the inversion acquisition of Abbott’s non-U.S. developed markets specialty and branded generics business.

Under the transaction, Mylan N.V., a new Dutch top holding company, will acquire these assets in exchange for approximately 21% of the shares in the new combined company Mylan N.V. with an approximate value of $5.3 billion, and Mylan Inc. will become a subsidiary of Mylan N.V. by means of a U.S. merger, resulting in the current Mylan shareholders owning approximately 79% of Mylan N.V. Mylan N.V. will be listed on the NASDAQ. The transaction is expected to complete in the first quarter of 2015 and is subject to closing conditions such as competition approvals and approval by Mylan Inc.’s shareholders.


Related experience

This website uses cookies. Some of these cookies are essential for the technical functioning of our website and you cannot disable these cookies if you want to read our website. We also use functional cookies to ensure the website functions properly and analytical cookies to personalise content and to analyse our traffic. You can either accept or refuse these functional and analytical cookies.

Privacy – en cookieverklaring